Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone Furoate HPA Axis Study in PAR
NCT00116818Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2005
- Primary completion
- May 2005
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of fluticasone in perennial allergic rhinitis (PAR) (3 arms), sponsored by GSK. Primary endpoint: Hypothalamic Pituitary Adrenocortical (HPA) axis function at 6 weeks. Started Jan 2005; status: completed.
02
Drugs
fluticasone
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT00116818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116818.